Malignant hyperthermia

Lancet

Volumn 352, Issue 9134, 1998, Pages 1131-1136

  Denborough, Michael ^a  

^a Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; DANTROLENE; RYANODINE RECEPTOR; SUXAMETHONIUM;

ANESTHESIA; DISEASE PREDISPOSITION; GENE MUTATION; HUMAN; MALIGNANT HYPERTHERMIA; MUSCLE FIBER MEMBRANE; PRIORITY JOURNAL; REVIEW;

EID: 0032480548     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03078-5     Document Type: Review

References (57)

1. Denborough MA, Lovell RRH. Anaesthetic deaths in a family. Lancet 1960; ii: 45.
2. Denborough MA, Forster JFA, Lovell RRH, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth 1962; 34: 395-96.
3. Gordon RA. Malignant hyperpyrexia during general anaesthesia. Can Anaesth Soc J 1996; 13: 415-16.
4. Denborough MA, Forster JFA, Hudson MC, Carter NG, Zapf P. Biochemical changes in malignant hyperpyrexia. Lancet 1970; i: 1137-38.
5. Denborough MA, Ebeling P, King JO, Zapf P. Myopathy and malignant hyperpyrexia. Lancet 1970; i: 1138-40.
6. Isaacs H, Barlow MB. Malignant hyperpyrexia during anaesthesia: possible association with clinical myopathy. BMJ 1970; i: 275-77.
7. Kalow W, Britt BA, Terreau MH, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970; ii: 895-98.
8. Ellis FR, Harriman DGF, Keaney NP, Kyei-Mensah K, Tyrrell JH. Halothane induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971; 43: 721-24.
9. Harriman DGF, Sumner DW, Ellis FR. Malignant hyperthermia myopathy. Q J Med 1973; 42: 639-64.
10. King JO, Denborough MA. Anesthetic-induced malignant hyperpyrexia in children. J Pediatr 1973; 83: 37-40.
11. Rosenberg H. The clinical syndrome. In: Brownell AKW, ed. Proceedings of Third International Symposium on Malignant Hyperthermia (Banff, Canada, 1982): 3-14.
12. Heiman-Patterson TD, Rosenberg HR, Binning CP, Tahmoush AJ. King-Denborough syndrome: contracture testing and literature review. Pediatr Neurol 1986; 2: 175-77.
13. Heiman-Patterson TD, Rosenberg H, Fletcher JF, Tahmoush AJ. Halothane contracture testing in neuromuscular diseases. Muscle Nerve 1988; 11: 453-57.
14. Isaacs H, Badenhorst MF. Dominantly inherited malignant hyperthermia (MH) in the King-Denborough syndrome. Muscle Nerve 1992; 15: 740-42.
15. Denborough MA, Dennett X, Anderson RMcD. Central-core disease and malignant hyperpyrexia. BMJ 1973; i: 272-73.
16. 31P-NMR spectroscopy: the metabolic profile of malignant hyperpyrexia porcine skeletal muscle. Muscle Nerve 1989; 12: 390-96.
17. Denborough MA. Heat stroke and malignant hyperpyrexia. Med J Aust 1982; i: 204-05.
18. Denborough MA. Clinical classification and incidence of malignant hyperthermia in Australia. In: Morio M, Kikuchi H, Yuge O, eds. Proceedings of the 3rd International Symposium on Malignant Hyperthermia. Tokyo: Springer-Verlag, 1996: 43-47.
19. Kozak-Ribbens G, Rodet L, Petrognani R, et al. Hyperthermie d'effort (HE): résultats des explorations de 55 patients. In: Novelli GP, Tegazzin V, eds. Workshop in Anaesthesia and Pharmacogenic Diseases: malignant hyperthermia. Minerva Anestésiol 1994; 60 (suppl 3): 177-81.
20. Denborough MA, Hopkinson KC. Firefighting and malignant hyperthermia. BMJ 1988; 296: 1442-43.
21. Caroff S, Rosenberg H, Gerber JC. Neuroleptic malignant syndrome and malignant hyperthermia. Lancet 1983; i: 244.
22. Downey GP, Rosenberg M, Caroff S, et al. Neuroleptic malignant syndrome: patient with unique clinical and physiological features. Am J Med 1984; 77: 338-40.
23. Delacour JL, Daoudal P, Chapoutot JL, Rocq B. Traitement du syndrome malin des neuroleptiques par le dautrolene. Nouv Presse Méd 1981; 10: 3572-73.
24. Boles JM, Lecam B, Mialon P, Pennec Y, Garve M. Hyperthermie maligne des neuroleptiques: guérison rapide par le dantrolene. Nouv Presse Méd 1982; 11: 674.
25. Coons DJ, Hillman FJ, Marshall RW. Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. Am J Psychiatry 1982; 139: 944-45.
26. Goekoop JG, Carbaat PA. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 1982; ii: 49-50.
27. May DC, Morris SW, Stewart RM, Fenton BJ, Gaffney FA. Neuroleptic malignant syndrome: response to dantrolene sodium. Ann Intern Med 1983; 98: 183-84.
28. Krivosic-Horber R, Adnet P, Guevart E, Theunynck D, Lestavel P. Neuroleptic malignant syndrome and malignant hypothermia: in vitro comparison with halothane and caffeine contracture tests. Br J Anaesth 1987; 59: 1554-56.
29. Collins SP, White MD, Denborough MA. The effects of calmodulin antagonist drugs on isolated sarcoplasmic reticulum from malignant hyperpyrexia susceptible swine. Int J Biochem 1987; 19: 819-26.
30. Denborough MA. Sudden infant death syndrome and malignant hyperpyrexia. Med J Aust 1981; i: 649-50.
31. Denborough MA, Galloway GJ, Hopkinson KC. Malignant hyperpyrexia and sudden infant death. Lancet 1982; ii: 1068-69.
32. Ording H, Ranklev E, Fletcher R. Investigation of malignant hyperthermia in Denmark and Sweden. Br J Anaesth 1984; 56: 1183-89.
33. Peterson DR, Davis N. Sudden infant death syndrome and malignant hyperthermia diathesis. Aust J Paediatr 1986; 22 (suppl): 33-35.
34. Ranklev E, Fletcher R, Krantz P. Malignant hyperthermia and sudden death. Am J Forensic Med Pathol 1985; 6: 149-50.
35. Ellis FR, Halsall PJ, Harriman DGF. Malignant hyperpyrexia and sudden infant death syndrome. Br J Anaesth 1988; 60: 28-30.
36. Hall LW, Woolf N, Bradley JWP, Jolly DW. Unusual reaction to suxamethonium chloride. BMJ 1966; ii: 1305.
37. Harrison GG, Biebuyck JF, Terblanche J, Dent DM, Hickman R, Sanders SG. Hyperpyrexia during anaesthesia. BMJ 1968; 3: 594-95.
38. Denborough MA, Hird FJR, King JO, et al. Mitochondrial and other studies in Australian Landrace pigs affected with malignant hyperpyrexia. In: Gordon RA, Britt BA, Kalow W, eds. International Symposium on Malignant Hyperthermia. Springfield, Illinois: Charles C Thomas. 1973: 229-37.
39. Ording H, Hald A, Sjontoft E. Malignant hyperthermia triggered by heating in anaesthetized pigs. Acta Anaesthesiol Scand 1985; 29: 698-701.
40. Denborough M, Hopkinson KC, O'Brien RO, Foster PS. Overheating alone can trigger malignant hyperthermia in piglets. Anaesth Intens Care 1996; 24: 348-54.
41. Galloway GJ, Denborough MA. Suxamethonium chloride and malignant hyperpyrexia. Br J Anaesth 1986; 58: 447-50.
42. Moulds RFW, Denborough MA. Identification of susceptibility to malignant hyperthermia. BMJ 1974; 2: 245-47.
43. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-69.
44. Sutko JL, Ito K, Kenyon JL. Ryanodine: a modifier of sarcoplasmic calcium release in striated muscle. Fed Proc 1985; 44: 2984-88.
45. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1990; 265: 2244-56.
46. 2+ release channel. J Biol Chem 1993; 268: 13765-68.
47. Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 488-51.
48. Otsu K, Phillips MS, Khanna VK, DeLeon S, MacLennan DH. Refinement of diagnostic assays for a probable causal mutation for porcine and human malignant hyperthermia. Genomics 1992; 13: 835-37.
49. MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 559-61.
50. McCarthy TV, Healy JMS, Heffron JJA, et al. Ryanodine receptor is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 562-64.
51. Deufel T, Golla A, Iles D, et al. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am J Hum Genet 1992; 50: 1151-61.
52. Quane KA, Keating KE, Manning BM, et al. Detection of a novel common mutant in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum Mol Genet 1994; 3: 471-76.
53. Haan EA, Freemantle CJ, McCure JA, Friend KL, Mulley JC. Assignment of the gene for central core disease to chromosome 19. Hum Genet 1990; 86: 187-90.
54. Ellis KO, Bryant SH. Excitation-contraction uncoupling in skeletal muscle by dantrolene sodium. Naunyn-Schmiedeberg's Arch Exp Pathol Pharmacol 1972; 274: 107-09.
55. Austin KL, Denborough MA. Drug treatment of malignant hyperpyrexia. Anaesth Intens Care 1977; 3: 207-13.
56. Harrison GG. Control of malignant hyperpyrexia syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975; 47: 62-65.
57. Kolb MS, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982; 56: 254-62.